Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

N.Z. Tamiflu Stocks Feared Ineffective Against New Flu Strain

This article was originally published in PharmAsia News

Executive Summary

New Zealand authorities fear the nation's stockpile of Roche's Tamiflu (oseltamivir) retroviral against influenza may not be useful due to a rapid spread of drug-resistant forms of the virus. In addition, 103 of the 1,229 treatment courses the government bought already have expired. World Health Organization tests showed a third of those with the H1N1 flu strain in South Africa had a drug-resistant form, even though only one of the 107 had been taking Tamiflu. Similar tests in 12 other countries through Aug. 20 also found H274Y mutations resistant to the drug. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069374

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel